NVSEF - Novartis hits main goal in Phase 3 trial for kidney disease therapy
2023-10-30 15:11:22 ET
More on Novartis, Novartis AG, etc.
- New And Improved Novartis
- Novartis AG (NVS) Q3 2023 Earnings Call Transcript
- Novartis AG (NVS) Shareholder Analyst Call (Transcript)
- Novartis reports Q3 earnings boosted by strong sales of key drugs and raises FY23 outlook
- Novartis Q3 2023 Earnings Preview
For further details see:
Novartis hits main goal in Phase 3 trial for kidney disease therapy